Research Strategy

Research on ALS
What makes ALS TDI so different from other biotech companies and research labs?
Our unique and comprehensive approach leverages more than a decade of treatment-focused ALS research and applies it on an industrial scale to get therapeutics to today’s ALS patients as quickly, efficiently, and cost-effectively as possible. Our research team evaluates the most promising therapeutic hypotheses through the lenses of the richest ALS research databases in the world. Treatments of all kinds are considered and tested rigorously and rapidly. Dr. Steve Perrin, CEO frequently speaks about our research plan to patients, families, industry executives and academics worldwide.

Click here to Read more about ALS TDI's research plan.
If you don’t find the answers you need here, feel free to ask us your question

Our Techniques

Gene Therapy

ALS TDI: Gene Therapy Gene Therapy is a highly targeted therapeutic approach designed to insert modified genes into cells in order to produce a potentially therapeutic protein or reduce production of a potentially toxic target. In a neurodegenerative disease like ALS there are multiple cell types potentially involved in disease including motor neurons, glial cells in the central nervous system, skeletal muscle, and peripheral immune cells. In order to reduce potential toxicity it is often necessary to target the gene therapy construct to specific tissues or even specific cell types within a given tissue.

Research Biology

ALS TDI: Research Biology The ALS Therapy Development Institute's scientists aim to discover and prioritize the most promising strategies to slow, stop, and reverse amyotrophic lateral sclerosis (ALS) disease progression. The Research Biology team dissects ALS pathology using broad genome-wide profiling technologies (trillions of data-points) integrated with high resolution studies of single proteins within single cells.

Validation & Biomarkers

ALS TDI: Validation & Biomarkers In vitro validation uses living cells grown in nutrient solutions for experiments that confirm the activity of promising therapeutics prior to initiation of longer and more costly in vivo (animal) studies. Many of the same technologies used to evaluate in vivo studies are also employed to interpret in vitro results. Biomarkers are biological signals that can be used to definitively diagnose a condition or disease and can also correlate with disease progression. Biomarkers can come from blood sampling, tissue biopsy, or less invasive techniques like skin elasticity measurement.

Testing Therapeutics

ALS TDI: Testing Therapeutics In vivo validation involves testing therapeutics in an animal model of disease. ALS TDI tests small molecules, gene therapies, biologics and stem cell products in its state-of-the-art research facility. Established in 1995, the SOD1 mouse model is internationally accepted as a robust model for ALS research. In 2008, ALS TDI published guidelines for the model's use and interpretation of experimental results.

Schedule a Lab Tour

We take our open-door philosophy and commitment to transparency very seriously. And, we love to show off.

Click here if you’d like to visit ALS TDI and get an up-close-and-personal look at the lab.

ALS TDI Scientist working in the lab

Virtual Lab Tour

Check outALS TDI's Virtual Lab Tour.

You'll be able to explore several areas of therapeutics that are part of the world's most comprehensive ALS research program.